We are proud to announce that APICES has been acknowledged for its ongoing collaboration in PALBOBIN Trial, a Phase IB clinical trial in Breast Cancer (TNBC). This acknowledgement was highlighted in the Journal of Cancer Research Communications.
APICES has contributed extensively to critical aspects throughout the trial, including start-up, coordination, project management, monitoring, and data management activities.
This acknowledgment is a great motivation for the entire APICES team to continue the commitment we bring to every project we collaborate on. We would like to congratulate to Ana Moreno, Susana Vara, Juan Luis Sanz and other colleagues from our Spain team involved in this trial. Your hard work and dedication make a real difference, and we are proud to have you representing APICES CRO in such impactful research.
We also sincerely thank PFIZER and Dr. Luis Manso for giving us the opportunity to support the study as CRO and for including us acknowledgments. We also congratulate them and all investigators and patients on the CABOMAYOR trial progress and results.
The PALBOBIN Trial was aimed at to evaluate palbociclib and binimetinib in advanced Breast Cancer TNBC after one or two prior therapies. Advanced, pre-treated TNBC has a dismal prognosis and lacks effective options beyond standard cytotoxics. We previously showed, via phosphoproteomic screening, that CDK6 and ERK hyperactivation are linked to adverse outcomes and represent actionable targets.
For further information about the PALBOBIN Trial, please visit: A phase IB study of binimetinib and palbociclib in molecularly selected advanced triple-negative breast cancer. | Cancer Research Communications | American Association for Cancer Research
Get the latest clinical insights delivered to your feed or inbox!
Key Takeaways: First-in-human trials in the EU are governed by Regulation (EU) No 536/2014 and the EMA’s first-in-human guideline (EMEA/CHMP/SWP/28367/07 Rev 1). Sponsors must submit a complete Clinical Trial Application via the CTIS portal and obtain both Part I...
Key Takeaways: Phase I dose escalation design in the EU is governed by ICH E8(R1), EMA first-in-human guidance (EMA/CHMP/SWP/28367/07 Rev.1), and EU Clinical Trial Regulation 536/2014 via CTIS. The classical 3+3 design is increasingly replaced by model-based...
EU MDR clinical investigation requirements have fundamentally changed how Medtech sponsors plan and execute device studies in Europe. Regulation (EU) 2017/745 replaced the clinical investigation provisions of Directive 93/42/EEC (MDD) and introduced a more stringent, harmonised framework across all 27 EU member states. For sponsors running investigations in Spain, Germany, France, the Netherlands, or any other member state, understanding which pathway applies to their study is the single most consequential regulatory decision before CIP submission.
